Suppr超能文献

酮替芬在尼泊尔哮喘儿童中的疗效和耐受性:一项临床研究。

Efficacy and tolerability of Ketotifen in Nepalese asthmatic children: a clinical study.

作者信息

Shakya K N, Joshi P, Piya A, Baral M R

机构信息

Kathmandu Medical College, Teaching Hospital, Sinamangal, Kathmandu, Nepal.

出版信息

Kathmandu Univ Med J (KUMJ). 2003 Oct-Dec;1(4):242-7.

Abstract

OBJECTIVE

To assess the efficacy of Ketotifen in asthmatic children and to record its adverse effects, if any.

DESIGN

Prospective clinical trial.

SETTING

Pediatric asthma follow up clinic of a teaching hospital.

PARTICIPANTS

23 asthmatic children between 3 and 15 years; 100% completed the trial on full protocol.

INTERVENTIONS

Ketotifen 1mg (adjusted according to body weight, 50 mcg/kg/dose) orally twice daily for 9 months.

PRIMARY OUTCOME

Decrease in frequency of asthmatic attacks and severity of exacerbations with improvements in peak expiratory flow rates (PEFR). Other measures included decrease in bronchodilator requirement, steroid doses and parental perception regarding patient quality of life.

RESULTS

34.78% children were symptom free by the end of 2nd 3 months and 65.21% had no further attack by the end of 3rd 3 months of Ketotifen prophylaxis. Those children with activity and sleep 'affected' (8.69%) and 'may be affected' (30.43%) together improved to 'may be affected' group (21.73%) by the end of 2nd 3 months and further reduced to 8.69% by the conclusion of 3rd 3 months. The duration of exacerbations was reduced in the remaining cases. Variability of PEFR decreased from 26.08% to 8.69% of children after the 3rd 3 months of Ketotifen prophylaxis. No significant adverse effect of therapy was observed during the study.

CONCLUSION

Oral Ketotifen is effective and well tolerated for use in prophylactic treatment of bronchial asthma in children.

摘要

目的

评估酮替芬对哮喘儿童的疗效,并记录其不良反应(如有)。

设计

前瞻性临床试验。

地点

一家教学医院的儿科哮喘随访诊所。

参与者

23名3至15岁的哮喘儿童;100%按完整方案完成试验。

干预措施

酮替芬1毫克(根据体重调整,50微克/千克/剂量),口服,每日两次,共9个月。

主要结局

哮喘发作频率降低,病情加重的严重程度减轻,同时呼气峰值流速(PEFR)有所改善。其他指标包括支气管扩张剂需求减少、类固醇剂量降低以及家长对患儿生活质量的认知。

结果

在酮替芬预防治疗的第2个3个月结束时,34.78%的儿童无症状,在第3个3个月结束时,65.21%的儿童未再发作。那些活动和睡眠“受影响”(8.69%)以及“可能受影响”(30.43%)的儿童,在第2个3个月结束时,合并改善至“可能受影响”组(21.73%),到第3个3个月结束时进一步降至8.69%。其余病例的病情加重持续时间缩短。在酮替芬预防治疗3个3个月后,儿童PEFR的变异性从26.08%降至8.69%。研究期间未观察到治疗的显著不良反应。

结论

口服酮替芬用于儿童支气管哮喘的预防性治疗有效且耐受性良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验